Built on the market-leading IN.PACT Admiral DCB technology, the IN.PACT 018 DCB is engineered to cross tight lesions and designed for better deliverability
News | Drug-Eluting Balloons
Medtronic Announces FDA Approval for IN.PACT 018 PTA Balloon Catheter

May 27, 2022 — Medtronic today announced approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 ...

Home May 27, 2022
Home
The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent (DES).
News | Drug-Eluting Balloons
MedAlliance’s SELUTION SLR Drug-eluting Balloon Receives FDA Investigational Device Exemption Approval

May 27, 2022 — The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a ...

Home May 27, 2022
Home
The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has identified this as a Class I recall, the most serious type of recall.
News | Cath Lab
Abbott Medical Recalls Dragonfly OpStar Imaging Catheter for Potential Loose Catheter Marker Band

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
At the 69th Annual Conference of the Israel Heart Society, UltraSight, an Israeli-based digital health pioneer transforming cardiac imaging through the power of artificial intelligence, and Sheba Medical Center Israel revealed new research findings from a blinded pilot study that validates the company’s technology, and confirms that UltraSight’s Artificial Intelligence (AI) guidance can allow any medical professional to successfully capture quality cardiac ultrasound images.
News | Artificial Intelligence
New Study Reveals UltraSight & Sheba Medical Center Enable Novice Ultrasound Users to Obtain Accurate, Diagnostic Quality Cardiac Images

May 26, 2022 — At the 69th Annual Conference of the Israel Heart Society, UltraSight, an Israeli-based digital health ...

Home May 26, 2022
Home
Late-breaking results presented at the European Society of Cardiology's Heart Failure Association annual conference and simultaneously published online in the European Journal of Heart Failure
News | Heart Failure
Axon Therapies Announces Positive Early Clinical Data from REBALANCE-HF Randomized Clinical Trial

May 26, 2022 — Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced ...

Home May 26, 2022
Home
The study found a gene called FMNL2 links cerebrovascular disease and Alzheimer’s and suggests changes in FMNL2 activity caused by cerebrovascular disease prevent the efficient clearance of toxic proteins from the brain, eventually leading to Alzheimer’s disease.
News | Cardiovascular Clinical Studies
Missing Link Between Alzheimer's and Vascular Disease Found?

May 26, 2022 — For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol ...

Home May 26, 2022
Home
Immune response and the lymphatic system are central to cardiac repair after a heart attack, according to a study from Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg Cardiovascular Research Institute.
News | Heart Failure
New Research Reveals How the Heart Repairs After a Heart Attack

May 25, 2022 — Immune response and the lymphatic system are central to cardiac repair after a heart attack, according to ...

Home May 25, 2022
Home
A section of a normal healthy heart (left) and three locations in a heart from a patient with arrhythmogenic cardiomyopathy. There are a lot more fat cells (large while spheres) in the diseased heart. Cardiomyocytes in the composite region often show signs of degeneration, as well as enhanced ZBTB11 expression
News | Cardiovascular Clinical Studies
New Gene Identified in Arrhythmogenic Cardiomyopathy

May 25, 2022 — Researchers from the group of Eva van Rooij used advanced sequencing technology to better understand the ...

Home May 25, 2022
Home
The ŌNŌ is intended to simplify bailout procedures in the expanding world of structural heart disease interventions
News | Structural Heart
ŌNŌCOR Receives FDA Clearance for Novel Endovascular Retrieval Technology

May 25, 2022 — ŌNŌCOR LLC, a leader in endovascular safety technology, today announced it has received 510(k) U.S. Food ...

Home May 25, 2022
Home
Thomas E. MacGillivray, MD
News | Cardiovascular Business
Thomas E. MacGillivray Named Chair of Cardiac Surgery for MedStar Heart & Vascular Institute

May 25, 2022 — MedStar Heart & Vascular Institute announced that Thomas E. MacGillivray, MD, has been named physician ...

Home May 25, 2022
Home
Amarin Corporation plc announced that research on the potential population health impact and cost-effectiveness of VASCEPA (icosapent ethyl), presented in two poster presentations at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions in Reston, VA, May 13-14, 2022
News | Pharmaceuticals
Research Presented at AHA's QCOR Scientific Sessions Indicate Potential for Vascepa to Reduce Major Adverse CV Events

May 24, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

Home May 24, 2022
Home
Continued research into efficacy of ensoETM for RF ablation procedures will support future regulatory efforts for expanded indications
News | EP Lab
First Patients Enrolled in IMPACT II Study

May 24, 2022 — Attune Medical, a pioneering medical device company with a technology platform based on temperature ...

Home May 24, 2022
Home
The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has initiated a voluntary nationwide recall of a single lot of Anagrelide Capsules, USP 0.5 mg (Lot number GD01090), to the consumer level in the United States.
News | Pharmaceuticals
Teva Issues Voluntary Nationwide Recall of One Lot of Anagrelide Capsules

May 24, 2022 — The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has ...

Home May 24, 2022
Home
Developed in collaboration with Janssen and Mayo Clinic, this technology has the potential to aid physicians in earlier detection of pulmonary hypertension, a progressive, life-threatening disease
News | Artificial Intelligence
FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm

May 24, 2022 — Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S ...

Home May 24, 2022
Home
A specific protein in blood vessel cells plays a major role in the development of vascular and cardiovascular diseases: The presence of too many "thromboxane A2 receptors" hinders the formation of new blood vessels.
News | Cardiovascular Clinical Studies
Researchers Find New Approach to Treating Cardiovascular Diseases

May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and ...

Home May 23, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now